STOCK TITAN

Recursion Pharmaceuticals Inc - RXRX STOCK NEWS

Welcome to our dedicated news page for Recursion Pharmaceuticals (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Recursion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Recursion Pharmaceuticals's position in the market.

Rhea-AI Summary
Recursion (NASDAQ: RXRX) to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8-11, 2024, showcasing its innovative approach to drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
conferences
-
Rhea-AI Summary
Recursion (RXRX) releases its third annual ESG Report, showcasing progress in reducing greenhouse gas emissions, enhancing diversity, and community impact. The company's commitment to sustainability and innovation in drug discovery is highlighted, earning accolades for ESG performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
-
Rhea-AI Summary
Recursion (RXRX) appoints Michael Bronstein as Scientific Advisor and opens a new office in London's King's Cross neighborhood to tap into Europe's TechBio talent pool. The company aims to expand its operations and advance drug discovery by hiring top talent and collaborating with AI experts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
none
Rhea-AI Summary
Recursion (RXRX) hosted its second annual Rare Disease Day event to raise awareness for rare diseases and support Utah's rare disease community. The event featured industry leaders and patient advocacy organizations aiming to accelerate diagnosis and treatment for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
-
Rhea-AI Summary
Recursion (RXRX) to participate in key investor conferences in March 2024, showcasing its innovative TechBio approach to drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
conferences
-
Rhea-AI Summary
Recursion (RXRX) reported business updates and financial results for Q4 2023 and FY 2023. The company made progress in causal AI modeling, launched LOWE for drug discovery, and provided updates on multiple clinical programs. Recursion's cash position decreased to $391.6 million, with total revenue at $10.9 million for Q4 2023. R&D expenses increased to $69.5 million, and net loss was $93.0 million for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.62%
Tags
Rhea-AI Summary
Recursion (NASDAQ: RXRX) will provide business updates and report its Q4 and full year 2023 financial results on February 27, 2024. The company will host its first L(earnings) Call to interact with the public and answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences earnings
-
Rhea-AI Summary
Altitude Lab's incubating startups have raised over $120M in early-stage funding since 2020. The launch of the Chris and Summer Gibson Founder Fellowship aims to support early-career scientists to launch their own startups. The fellowship offers up to $100,000 in funding, scientific tools, laboratories, and monthly mentoring with Chris Gibson to two fellows each year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Summary
Recursion (NASDAQ: RXRX) presents LOWE, its new LLM-based software for drug discovery at an invite-only event with NVIDIA. The software uses natural language interface to orchestrate wet-lab and dry-lab components of Recursion OS, offering a glimpse into the future of autonomous 'AI scientists' for therapeutic discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
none
Rhea-AI Summary
Recursion (RXRX) signs agreement with Bayer AG to in-license a potential first-in-class novel molecule emerging from fibrosis research collaboration. The compound has shown early data suggesting the potential to reverse disease-related fibrotic processes, addressing high unmet need for patients with fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.65%
Tags
none
Recursion Pharmaceuticals Inc

Nasdaq:RXRX

RXRX Rankings

RXRX Stock Data

2.09B
187.99M
5.77%
92.41%
18.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Salt Lake City

About RXRX

recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.